CTx Partner, Bionomics Receives Share of Funds from License Deal for Cancer and Blood Disorder Inhibitors

1 year ago  •  By  •  0 Comments

Australian drug development company Bionomics Limited (ASX:BNO, OTCQX:BNOEF) has received US$736,815 in licensing funds as part of an agreement between MSD (known as Merck in the US & Canada) and Cancer Research Technologies (CRT) on behalf of the Australian Cooperative Research Centre for Cancer Therapeutics (CTx).

Read the Full Press Release